| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 124,302 | 140,594 | 118,966 | 278,308 |
| Bargain purchase gain | 1,118 | 3,343 | 3,800 | 110,561 |
| Acquired in-process research and development | NaN | 0 | NaN | NaN |
| Depreciation and amortization | 69,856 | 69,011 | 71,126 | 136,705 |
| Amortization of premiums on marketable securities | NaN | NaN | 53 | 421 |
| Provision for excess and obsolete inventory | 4,960 | 6,131 | 5,055 | 10,933 |
| Amortization of inventory fair value step-up | NaN | NaN | 6,958 | 6,015 |
| Net (gain)/loss from foreign currency adjustment | NaN | NaN | 3,279 | 11,342 |
| Amortization of 2025 notes fair value step-up | NaN | NaN | 0 | 6,658 |
| Amortization of acquisition accounting fair value step up | 0 | 26,112 | NaN | NaN |
| Stock-based compensation expense | 12,617 | 11,418 | 11,538 | 26,823 |
| Allowance for expected credit losses | 5,277 | 4,912 | 757 | 4,554 |
| Change in fair value of business acquisition liabilities | 6,352 | 10,794 | -2,721 | 5,389 |
| Change in deferred income taxes | 7,962 | 18,100 | 41,761 | -41,236 |
| (gain)/loss on disposal of assets, net | -2,449 | -4,087 | -2,307 | -6,131 |
| Payment of business acquisition-related liabilities | 2,273 | 593 | 661 | 15,764 |
| Net (gain)/loss from foreign currency adjustment | 98 | -12,591 | NaN | NaN |
| Accounts receivable | 13,399 | 64,153 | 8,424 | -20,395 |
| Inventories | 16,651 | 178 | 5,698 | 11,722 |
| Prepaid expenses and other assets | -6,942 | -17,821 | 7,541 | -852 |
| Accounts payable | 5,082 | 9,141 | 3,431 | -4,085 |
| Accrued expenses and other liabilities | -24,668 | 8,775 | 39,283 | -13,841 |
| Income taxes payable/receivable | 14,576 | 7,085 | -19,310 | -38,626 |
| Net cash provided by/(used in) operating activities | 202,364 | 248,587 | 249,695 | 255,165 |
| Purchases of marketable securities | 146,393 | 70,422 | 35,359 | 1,750 |
| Maturities of marketable securities | NaN | 5,250 | 0 | 58,630 |
| Repayments of borrowings from credit facility | NaN | NaN | NaN | 20,000 |
| Acquisition of intangible assets | NaN | 80 | 4,666 | 5,000 |
| Proceeds from credit facility | NaN | NaN | NaN | 20,000 |
| Sales of marketable securities | NaN | 0 | 0 | 115,608 |
| Sales and maturities of marketable securities | 8,243 | NaN | NaN | NaN |
| Proceeds from credit facility | NaN | NaN | 20,000 | NaN |
| Purchases of property and equipment | 39,615 | 46,197 | 35,817 | 82,665 |
| Repayments of borrowings from credit facility | NaN | NaN | 20,000 | NaN |
| Acquisition of businesses, net of cash acquired and purchases of intangible and other assets | 4,909 | 0 | 0 | 252,546 |
| Net cash provided by/(used in) investing activities | -182,674 | -111,449 | -75,842 | -167,723 |
| Repayment of senior convertible notes | NaN | NaN | 0 | 449,985 |
| Payment of business acquisition-related liabilities | 4,324 | 4,332 | 3,376 | 7,864 |
| Net proceeds from exercise of stock options | 25,961 | 62,758 | 11,079 | 15,920 |
| Payments related to tax withholdings for share-based compensation | 3,440 | 211 | -255 | 2,953 |
| Repurchase of common stock | 0 | 45,000 | 40,000 | 215,451 |
| Repayment of senior convertible notes | 0 | 449,985 | NaN | NaN |
| Net cash provided by/(used in) financing activities | 18,197 | 13,215 | -32,042 | -660,333 |
| Effect of foreign exchange rates on cash | -3,093 | 4,034 | 512 | 17,899 |
| Net increase/(decrease) in cash and cash equivalents | 34,794 | 154,387 | 142,323 | -554,992 |
| Cash and cash equivalents at beginning of period | 526,156 | 371,769 | 784,438 | NaN |
| Cash and cash equivalents at end of period | 560,950 | 526,156 | 371,769 | NaN |
GLOBUS MEDICAL INC (GMED)
GLOBUS MEDICAL INC (GMED)